(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV/c compared to 60% in control groups
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 https://doi.org/10.1093/ofid/ofaa241 In this single-center, randomized, and open-label trial, mild patients with COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top… Continue reading "(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV/c compared to 60% in control groups"